AB Science S.A (AB.PA) Diversifiers

Equity · Currency in EUR · Last updated Jun 5, 2026

AB Science S.A. designs and develops novel drugs targeting inflammatory diseases, nervous system pathologies, and cancers, with its lead compound masitinib undergoing Phase III trials for multiple serious conditions including amyotrophic lateral sclerosis and severe asthma. The company is also developing AB8939 for acute myeloid leukemia and markets masitinib under the Masivet brand in Europe.

Looking to balance out your exposure to AB.PA? The ETFs below have the lowest correlation with AB.PA — they tend to move on their own, which can help reduce risk when AB.PA drops. The stock ideas table highlights individual companies that behave independently from AB.PA.

No Diversifiers Found for AB.PA

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements AB.PA

Add AB.PA to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with AB.PA